NMC warns against admission in undergraduate courses at four foreign medical colleges, issues advisory
Failure to adhere to the advisory will result in ineligibility for medical registration in India, the NMC stated.
The medical colleges in question are:
Central American Health and Sciences University, Belize
Columbus Central University, Belize
Washington University of Health and Sciences, Belize
Chirchik Branch of Tashkent State Medical University, Uzbekistan
The alert was issued after the Indian Embassy in Mexico and the Eurasia Division of the Ministry of External Affairs raised serious concerns that these institutions were not meeting the required Indian standards in medical education.
'It is also advised that, before seeking admission to any foreign medical institute or university, prospective students and their parents carefully read the alert/advisory uploaded on the National Medical Commission (NMC) website dated 19th May 2025.
The advisory contains critical information regarding recognised institutions, eligibility criteria, and other important guidelines,' said the alert issued by Sukh Lal Meena, Director, Under-Graduate Medical Education Board (UGMEB).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
ICT Mumbai biocluster receives catalytic funding to boost translational biopharma research
Mumbai: In a significant boost to India's translational research ecosystem, ICT Mumbai's Biocluster secured Rs 30 crore in catalytic funding from the Indian Translational Research Institute (ITRI). The translational biopharmaceutical facility aims to bridge the gap between lab-stage research and clinical application. The eight-storey cluster will focus on rare diseases, synthetic biology, and AI-driven drug development. It will house a GMP-ready biologics pilot plant, shared R&D infrastructure, and advanced training zones for workforce development. Dr Ratnesh Jain, Principal Investigator of the project, said the Biocluster aims to make Indian biopharma globally competitive. ITRI CEO Dr Abdur Rub emphasised the need to de-risk innovation and scale healthcare solutions. Positioned as a national translational platform, the Mumbai Biocluster seeks to empower startups, academia, and industry alike—enabling faster, capital-efficient transitions from research to real-world impact. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai
Time of India
2 hours ago
- Time of India
Ayurvedic doctor shares what a proper healthy day looks like and what should NOT be done
Let's be honest, life's hectic these days. Most of us barely stop to breathe, let alone think about our daily routines. But funny enough, it's often the small, steady habits that keep us sane. Ayurveda! The old Indian system of health has a few ideas about how to live better. And no, it's not just about herbs and oils. A lot of it is about timing up your daily life with the body's own natural rhythm. They've got a word for it: Dinacharya . It basically means 'daily routine'. Nothing too wild. Just doing things at the right time. Sounds obvious, but it's easy to forget. Starting with the mornings. There's this window, from like 3 AM to 7:30 AM, that's supposed to be ideal for getting up and going. Apparently the first half is ruled by something called Vata, which makes it easier to wake up with a clear head. Once the sun's up, Kapha kicks in, and that's when things feel heavier. So, getting out of bed earlier kind of gives you a head start. What do you do after waking? Well, scrape your tongue, swish a bit of oil around your mouth (oil pulling, they call it), and drink some copper-vessel water if you have one lying around. Sounds odd, but these old tricks are supposed to help get your digestion moving. A bit of stretching or yoga? That's next. Nothing fancy. Maybe 10–15 minutes tops. Throw in some deep breathing or sit quietly. Keeps the stress down and helps your body do its thing. Hormones stay balanced. People feel better. Image : Canva Breakfast? Keep it simple. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Remember Him? Take A Deep Breath Before You See Him Now The Noodle Box Undo Soaked almonds or dates are good. Even some roasted mung bean flour mixed with buttermilk (or lassi) is filling but not heavy. You want fuel, not a food coma. Midday is when your digestion's at its strongest. Around 12 to 1 PM. So, that's when to eat your biggest meal. If you're gonna have something rich or protein-heavy, this is the time. Your body can actually handle it now. By late afternoon, around 3 or 4 PM, you'll probably want a light snack. Nothing big. A piece of fruit or two. Just enough to stop you from crashing. Evenings around 5 to 7 PM is the good time to move. Whether that's a jog, the gym, or just a walk, this is when your muscles are ready to go. After that, slow things down. From 7 PM onwards, you should start switching off. Not saying you need to sit in silence, but maybe ditch the emails. Listen to music. Talk to someone. Do some candle gazing (Trataka), if that's your thing. Light dinner too. Vegetarian's best. Don't eat too late, it messes with your sleep and digestion. Now, this part matters: 10 PM to 2 AM is when your body does the heavy lifting, repairing, restoring, regenerating. If you're still awake scrolling Instagram, you're messing with that process. Try to be asleep by 10. Keep the room dark. Skip the screens. Let your brain and body rest properly. In the end, it's not about being perfect. Ayurveda just gives you a bit of a roadmap. Not a rulebook. Even if you follow a few of these suggestions, wake up earlier, eat when your digestion's strong, sleep on time, you'll likely feel better. (By Dr Somit Kumar, M.D (Ayu), PhD, Chief Scientific Officer & Director of Research, AVP Research Foundation)
Time of India
2 hours ago
- Time of India
Cheaper cancer care therapy earns big bucks for pharma company
ImmunoAct, an Indian cell and gene therapy company, has achieved profitability in its first full year, generating ₹62 crore in revenue and ₹12 crore in profit before tax in FY25. Its NexCAR19, an affordable CAR-T therapy, has been administered to over 350 patients across India. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads India's cell and gene therapy pioneer ImmunoAct has turned profitable in its first full year of operations, a rare feat in the country's emerging startup landscape where research-based pharma enterprises encounter serious scale and cash flow in which Hyderabad-based drugmaker Laurus Labs has roughly 34% equity stake, saw revenues of ₹62 crore with a profit before tax of ₹12 crore in FY25, according to sources. The year before, ImmunoAct had revenues of ₹11 by immunologist Rahul Purwar in 2013, ImmunoACT was spun off from the department of bioengineering department of IIT Bombay in NexCAR19 is the first indigenously developed breakthrough cancer CAR-T (chimeric antigen receptor T-cell) therapy approved by India's central drug regulatory agency in October was formally launched in India in April 2024 at a price ~90% cheaper than its US and European counterparts like Novartis and Gilead, making it far more affordable for India and low-and-middle income countries, on its potential approval. So far, the therapy has been infused in over 350 patients across 70 hospitals in CAR-T treatment, the patient's immune cells are extracted and through a maze of re-engineering processes infused back to recognize and kill cancer cells, giving a longer remission to patients as compared to the conventional options like immunotherapy or bone marrow transplants. The therapy is used when all other options are CAR-T dose (one-and-done infusion) costs around ₹30 lakh, which was initially priced at ₹42 lakh, and is expected to see a further decline as demand picks ImmunoACT has recently appointed former managing director of Roche India V Simpson Immanuel as its strategic Purwar added, "We needed someone who understands not just the commercial landscape, but also the nuances of innovation, patient access, and global expansion."Earlier this year, Immuneel Therapeutics, backed by leading names like Kiran Mazumdar-Shaw and globally renowned oncologist Siddhartha Mukherjee secured approval for Qartemi, its cell therapy for adult B-cell non-Hodgkin Lymphoma, in India. Companies like Cipla , Dr Reddy's Labs and Bharat Biotech are investing heavily in new CAR-Ts are at the frontiers of a range of cancer treatments, attracting billions of dollars in investments from large drugmakers. The market for such therapies is expected to touch $134 billion by 2034 from around $10 billion at present.
